Is oncocyte (OCX) a good stock to buy?
OncoCyte has received 71.92% “outperform” votes from our community. MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote “Outperform” if you believe OCX will outperform the S&P 500 over the long term.
Where can I buy shares of OCX?
Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is oncocyte efficiently growing its dividend?
OncoCyte does not have a long track record of dividend growth. In the past three months, OncoCyte insiders have not sold or bought any company stock. Only 4.06% of the stock of OncoCyte is held by insiders. 80.65% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Is OCX stock a good Buy?
OncoCyte Corp (NASDAQ:OCX) The 6 analysts offering 12-month price forecasts for OncoCyte Corp have a median target of 3.13, with a high estimate of 6.00 and a low estimate of 1.25. The median estimate represents a +243.41% increase from the last price of 0.91.
Should I buy OncoCyte stock?
OncoCyte has 141.89% upside potential, based on the analysts' average price target. Can I see which stocks the top-ranking analysts are rating? Yes, go to the Analysts' Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
What is OncoCyte's consensus rating and price target?
According to the issued ratings of 5 analysts in the last year, the consensus rating for OncoCyte stock is Buy based on the current 1 hold rating a...
Do Wall Street analysts like OncoCyte more than its competitors?
Analysts like OncoCyte stock more than the stock of other Medical companies. The consensus rating score for OncoCyte is 2.80 while the average cons...
Do MarketBeat users like OncoCyte more than its competitors?
MarketBeat users like OncoCyte stock more than the stock of other Medical companies. 70.15% of MarketBeat users gave OncoCyte an outperform vote wh...
Is OncoCyte being downgraded by Wall Street analysts?
Over the previous 90 days, OncoCyte's stock had 1 downgrade by analysts.
Does OncoCyte's stock price have much upside?
According to analysts, OncoCyte's stock has a predicted upside of 142.91% based on their 12-month price targets.
What analysts cover OncoCyte?
OncoCyte has been rated by Lake Street Capital , Needham & Company LLC , Piper Sandler , and Stephens in the past 90 days.
Should I buy or sell OncoCyte stock right now?
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 1 hold ra...
What is OncoCyte's stock price forecast for 2022?
5 equities research analysts have issued 1-year price objectives for OncoCyte's stock. Their forecasts range from $1.40 to $6.00. On average, they...
How has OncoCyte's stock price performed in 2022?
OncoCyte's stock was trading at $1.89 at the beginning of the year. Since then, OCX shares have decreased by 37.6% and is now trading at $1.18. Vi...
How were OncoCyte's earnings last quarter?
OncoCyte Co. (NYSEAMERICAN:OCX) released its earnings results on Wednesday, May, 11th. The biotechnology company reported ($0.11) earnings per shar...
Who are OncoCyte's key executives?
OncoCyte's management team includes the following people: Mr. Ronald A. Andrews Jr. , Pres, CEO & Director (Age 62, Pay $801.84k) Mr. Mitchell S...
Who are some of OncoCyte's key competitors?
Some companies that are related to OncoCyte include Alpha Teknova (TKNO) , VolitionRx (VNRX) , VolitionRx (VNRX) , MyMD Pharmaceuticals (MYMD)...
What other stocks do shareholders of OncoCyte own?
Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include Alibaba Group (BABA) , Bro...
What is OncoCyte's stock symbol?
OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."
Who are OncoCyte's major shareholders?
OncoCyte's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.35%), Vanguar...
About OncoCyte
OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO.
OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OncoCyte stock. View analyst ratings for OncoCyte or view top-rated stocks.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
The Trend in the Analyst Price Target
OCX's average price target has moved down $1.87 over the prior 32 weeks.
The Trend in the Broker Recommendations
OCX's average broker recommendation rating improved by 0.13 over the prior 62 days.
Price Target and Analyst Ratings
Piper Sandler is very positive about OCX and gave it a "Overweight" rating on Dec 16, 2020. The price target was changed from $2.00 to $4.00.
OCX Stock Trend
The stock lies in the lower of a very wide and falling trend in the short term, and this may normally pose a very good buying opportunity. If the lower trend floor at $1.60 is broken, it will firstly indicate a stronger fall rate.
How much is Oncocyte's net loss for the first quarter of 2021?
Cash used in operations was approximately $9.8 million for the first quarter of 2021.
How much was the operating loss in 2021?
Operating losses, as reported, for the first quarter of 2021 were $11.4 million, an increase of $3.0 million from $8.4 million as compared to the first quarter of 2020. Operating losses, on an adjusted basis, were $8.6 million, an increase of $1.2 million from $7.4 million as compared to the first quarter of 2020.
How much will research and development cost in 2021?
Research and development expenses for the first quarter of 2021 were $3.4 million as compared to $2.2 million for the same period in 2020, an increase of $1.2 million, primarily due to increased investment in DetermaIO, personnel and related expenses.
How much is the first quarter of 2021?
Consolidated revenues for the first quarter of 2021 were approximately $1.12 million, a 123% increase from the fourth quarter of 2020, as revenues from both sources increased over the fourth quarter of 2020.
What is the name of the CDX for cancer?
Amgen and QIAGEN originally initiated their collaboration to develop a tissue-based CDx for investigational cancer treatment with AMG 510, now named LUMAKRAS, which is the first KRAS G12C inhibitor to advance to the clinic targeting the KRAS G12C oncogene, one of the genes most frequently mutated in human cancers.
Is DetermaRx a cash or accrual test?
Accordingly, DetermaRx tests performed for both Medicare covered patients and Medicare Advantage covered patients are being recognized when the tests are performed, on an accrual basis, at the Medicare rate, rather than on a cash basis.